bendamustine hydrochloride has been researched along with Disease Exacerbation in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (14.29) | 29.6817 |
| 2010's | 20 (71.43) | 24.3611 |
| 2020's | 4 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Belada, D; Boccomini, C; Deshpande, S; Dreyling, M; Flinn, IW; Giri, P; Goy, A; Hamlin, PA; Henninger, T; Hermine, O; Hernández-Rivas, JÁ; Hong, X; Howes, A; Jerkeman, M; Jurczak, W; Kim, SJ; Le Gouill, S; Lewis, D; Mishima, Y; Özcan, M; Perini, GF; Pocock, C; Qin, R; Song, Y; Spurgeon, SE; Storring, JM; Trotman, J; Walewski, J; Wang, ML; Zhu, J; Zinzani, PL | 1 |
| Allan, JN; Barr, PM; Billio, A; Brander, DM; Cavallari, M; Cimino, G; Coscia, M; Cucci, R; Cuneo, A; de la Serna, J; Di Raimondo, F; Doubek, M; Farina, L; Ferrarini, I; Foà, R; Gaidano, G; Gentile, M; Ghia, P; Hill, BT; Ilariucci, F; Jacobs, R; Lamanna, N; Lansigan, F; Laurenti, L; Marchetti, M; Mato, AR; Mauro, FR; Medina Perez, A; Molica, S; Orlandi, EM; Pagel, JM; Piciocchi, A; Pu, JJ; Rigolin, GM; Roeker, L; Schuster, SJ; Sehgal, AR; Shadman, M; Shah, NN; Skarbnik, AP; Spacek, M; Tam, CS; Tedeschi, A; Trentin, L; Ujjani, CS; Vignetti, M; Winter, A | 1 |
| Arasaretnam, A; Bishton, M; Bolam, S; Creasey, T; Crosbie, N; Dawi, S; Dutton, D; Eyre, TA; Follows, G; Goradia, H; Harrison, S; Johnston, R; Kirkwood, AA; Lambert, J; Lewis, D; McCulloch, R; McKay, P; McMillan, A; Miles, O; Osborne, W; Patmore, R; Phillips, N; Robinson, A; Rule, S; Wilson, MR | 1 |
| Al-Rohil, RN; Kheterpal, MK; Leckey, BD; Selim, MA | 1 |
| Campioni, M; DeCosta, L; Fink, L; Flinois, A; Gazzola, C; Gonzalez-McQuire, S; Leleu, H; Mennini, FS; Schoen, P; Yong, K | 1 |
| Hong, SH; Kang, JH; Kim, YS; Kwak, YK; Lee, SW; Sung, S | 1 |
| Bonaldi, L; Martines, A; Nabergoj, M; Piazza, F; Pizzi, M; Scapinello, G; Semenzato, G; Trentin, L; Vio, S; Visentin, A | 1 |
| Agarwal, S; Cordero, J; de Vos, S; Dunbar, M; Enschede, SH; Flowers, CR; Fowler, N; Kozloff, M; Nastoupil, LJ; Nolan, C; Petrich, AM; Reid, E; Ross, JA; Salem, AH; Swinnen, LJ; Verdugo, M; Wang, D; Zhou, L | 1 |
| Aguiar, D; Alfaro, J; Alvarez, R; Blasco, A; Calvo, V; Casanova, M; de la Cruz Merino, L; García-Arroyo, FR; Herrero, J; Llanos, M; Martinez-Banaclocha, N; Provencio, M; Quero, C; Rodriguez-Abreu, D; Rueda, A | 1 |
| Aletaha, D; Coates, LC; Ganz, F; Hojnik, M; Landewé, R; Ritchlin, CT; Zhang, Y | 1 |
| Berdeja, JG; Daniel, DB; Erter, J; Flinn, IW; Mace, JR | 1 |
| Cafferty, F; Connors, JM; Farinha, P; Ferguson, D; Freeman, CL; Gerrie, AS; Kridel, R; Moccia, AA; Savage, KJ; Scott, DW; Sehn, LH; Skinnider, B; Slack, GW; Villa, DR | 1 |
| Adamopoulos, AM; Falchook, GS; Fortier, A; Fu, S; Hess, KR; Hong, D; Janku, F; Kurzrock, R; Naing, A; Piha-Paul, S; Tsimberidou, AM; Wheler, J; Ye, Y | 1 |
| Advani, RH; Anderson, KC; Barlogie, B; Dimopoulos, MA; García-Sanz, R; Gertz, MA; Ghobrial, IM; Gregory, SA; Kastritis, E; Kimby, E; Kyle, RA; Kyriakou, C; Landgren, O; Leblond, V; Leleu, X; Maloney, D; Merlini, G; Morel, P; Morra, E; Munshi, N; Owen, RG; Rummel, M; Terpos, E; Thomas, SK; Treon, SP | 1 |
| Dong, F; Ke, X; Li, H; Wan, W; Wang, J; Wang, Y; Wu, F; Yan, X; Zhang, W; Zhu, M | 1 |
| Arcaini, L; Baldini, L; Carella, AM; Cesaretti, M; Goldaniga, M; Luminari, S; Orsucci, L; Pinto, A; Pulsoni, A; Salvi, F; Stelitano, C; Tedeschi, A; Tucci, A | 1 |
| Brugger, W; Cheson, BD; Damaj, G; Dreyling, M; Kahl, B; Kimby, E; Ogura, M; Weidmann, E; Wendtner, CM; Zinzani, PL | 1 |
| Avigdor, A; Balasubramanian, S; Bartlett, NL; Chanan-Khan, A; Cramer, P; Demirkan, F; Dilhuydy, MS; Fraser, G; Goy, A; Grosicki, S; Hallek, M; Howes, A; Janssens, A; Karlsson, C; Loscertales, J; Mahler, M; Mato, A; Mayer, J; Panagiotidis, P; Pavlovsky, MA; Phelps, C; Pristupa, A; Pylypenko, H; Rule, S; Salman, M; Samoilova, O; Silva, RS; Sun, S; Villa, D | 1 |
| Blank, J; Chang, JE; Eickhoff, J; Go, RS; Havighurst, T; Kahl, BS; Kim, K; Kirby-Slimp, R; Traynor, AM; Volk, LM; Weiss, M; Werndli, J | 1 |
| Anderlini, P; Cheah, CY; Chihara, D; Fanale, MA; Fayad, LE; Fowler, NH; Hagemeister, FB; Horowitz, S; Nastoupil, LJ; Neelapu, SS; Nieto, Y; Oki, Y; Rodriguez, MA; Romaguera, JE; Samaniego, F; Sevin, A; Turturro, F; Wang, M; Westin, JR; Zhou, S | 1 |
| Venkatesan, P | 1 |
| Badiali, S; Bari, A; Cocito, F; Corso, A; Gentile, M; Guarini, A; Marcheselli, L; Marcheselli, R; Mazzone, C; Mele, G; Minoia, C; Morabito, F; Musto, P; Palumbo, A; Pozzi, S; Ria, R; Rivolti, E; Sacchi, S; Vincelli, I | 1 |
| Abarah, W; Bachy, E; Braun, T; Broussais, F; Cartron, G; Choufi, B; Clavert, A; Damaj, G; Fornecker, LM; Fruchart, C; Gac, AC; Garidi, R; Gaulard, P; Gyan, E; Herbaux, C; Houot, R; Jaccard, A; Joly, B; Le Bras, F; Maisonneuve, H; Malak, S; Marin, E; Martignoles, JA; Morschhauser, F; Parcelier, A; Pham, AD; Reboursiere, E; Rossi, C; Safar, V; Schirmer, L; Sibon, D; Tilly, H; Tournilhac, O; Tricot, S | 1 |
| Ahmadi, T; Maniar, T; Schuster, S; Stadtmauer, E | 1 |
| Alsina, M; Anderson, KC; Bensinger, W; Biermann, JS; Cohen, AD; Devine, S; Djulbegovic, B; Faber, EA; Gasparetto, C; Hernandez-Illizaliturri, F; Huff, CA; Kassim, A; Krishnan, AY; Kumar, R; Liedtke, M; Meredith, R; Raje, N; Schriber, J; Shead, DA; Singhal, S; Somlo, G; Stockerl-Goldstein, K; Treon, SP; Weber, D; Yahalom, J; Yunus, F | 1 |
| Heymanns, J; Köppler, H; Pandorf, A; Weide, R | 1 |
| Caca, K; Kreth, F; Mössner, J; Preiss, R; Schoppmeyer, K; Wiedmann, M | 1 |
| Bruns, I; Czibere, A; Fenk, B; Fenk, R; Graef, T; Haas, R; Kobbe, G; Michael, M; Neumann, F; Zohren, F | 1 |
3 review(s) available for bendamustine hydrochloride and Disease Exacerbation
| Article | Year |
|---|---|
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Consensus Development Conferences as Topic; Disease Progression; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2014 |
Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Consensus Development Conferences as Topic; Disease Management; Disease Progression; Drug Resistance; Hematologic Diseases; Hematologic Neoplasms; Humans; Recurrence; Retreatment | 2016 |
Chronic lymphocytic leukemia: new concepts and emerging therapies.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocyte Subsets; Bendamustine Hydrochloride; CD5 Antigens; Disease Progression; Drugs, Investigational; Humans; Immunologic Factors; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Neoplasm, Residual; Nitrogen Mustard Compounds; Prognosis; Randomized Controlled Trials as Topic; Salvage Therapy | 2009 |
12 trial(s) available for bendamustine hydrochloride and Disease Exacerbation
| Article | Year |
|---|---|
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progression; Humans; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Remission Induction; Rituximab; Survival Analysis | 2022 |
Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Chemotherapy-Induced Febrile Neutropenia; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Rituximab; Salvage Therapy; Sulfonamides | 2018 |
Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphoma, Follicular; Maintenance Chemotherapy; Male; Middle Aged; Progression-Free Survival; Prospective Studies; Remission Induction; Rituximab; Spain | 2019 |
Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity.
Topics: Adalimumab; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Psoriatic; Bendamustine Hydrochloride; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Foot Joints; Hand Joints; Humans; Male; Methotrexate; Middle Aged; Radiography; Young Adult | 2019 |
Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Feasibility Studies; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Prednisone; Rituximab; Standard of Care; Vincristine | 2019 |
Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bevacizumab; Disease Progression; Female; Humans; Male; Middle Aged; Neoplasms; Nitrogen Mustard Compounds; Treatment Outcome; Young Adult | 2014 |
A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bone Marrow; Disease Progression; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Remission Induction; Rituximab; Treatment Outcome | 2016 |
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Bendamustine Hydrochloride; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Hemorrhage; Humans; Intention to Treat Analysis; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nausea; Neutropenia; Piperidines; Pyrazoles; Pyrimidines; Retreatment; Rituximab; Thrombocytopenia | 2016 |
Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Remission Induction; Rituximab; Thalidomide; Treatment Outcome | 2016 |
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Staging; Recurrence; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome | 2017 |
Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Bendamustine Hydrochloride; Disease Progression; Drug Therapy, Combination; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Nitrogen Mustard Compounds; Outpatients; Pilot Projects; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Rituximab; Survival Rate; Time Factors; World Health Organization | 2004 |
A pilot study of bendamustine in advanced bile duct cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bendamustine Hydrochloride; Bile Duct Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Liver Function Tests; Male; Metabolic Detoxication, Phase II; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Pilot Projects | 2007 |
13 other study(ies) available for bendamustine hydrochloride and Disease Exacerbation
| Article | Year |
|---|---|
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
Topics: Adenine; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progression; Europe; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Rituximab; Time Factors; United States | 2020 |
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Disease Progression; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Outcome Assessment, Health Care; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Recurrence; Retrospective Studies; Rituximab; State Medicine; United Kingdom; Withholding Treatment | 2021 |
Cutaneous involvement by T-cell prolymphocytic leukemia presenting as livedoid vasculopathy.
Topics: Aged; Alemtuzumab; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Bendamustine Hydrochloride; Biopsy; Diagnosis, Differential; Disease Progression; Exanthema; Extremities; Fatal Outcome; Humans; Hyperpigmentation; Immunohistochemistry; Leukemia, Prolymphocytic, T-Cell; Male; Skin Neoplasms; Torso; Vascular Diseases | 2021 |
Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progression; Female; France; Health Expenditures; Health Resources; Hospitalization; Humans; Italy; Lenalidomide; Male; Middle Aged; Models, Econometric; Multiple Myeloma; Retrospective Studies; Thalidomide; United Kingdom | 2018 |
Intracranial control and survival outcome of tyrosine kinase inhibitor (TKI) alone versus TKI plus radiotherapy for brain metastasis of epidermal growth factor receptor-mutant non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bendamustine Hydrochloride; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; ErbB Receptors; Female; Humans; Incidence; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2018 |
Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine.
Topics: Abnormal Karyotype; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Lineage; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Disease Progression; Female; Genes, Immunoglobulin; Genes, myc; Humans; Immunoglobulin Heavy Chains; Lymphocytes; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Remission Induction; Rituximab; Splenic Neoplasms; Translocation, Genetic; Trisomy | 2018 |
Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bendamustine Hydrochloride; Disease Progression; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Retrospective Studies; Rituximab; Young Adult | 2019 |
B7-H3 silencing inhibits tumor progression of mantle cell lymphoma and enhances chemosensitivity.
Topics: Animals; Antineoplastic Agents; Apoptosis; B7 Antigens; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Female; Gene Silencing; Humans; Lymphoma, Mantle-Cell; Mice; Neoplasms, Experimental; Rituximab | 2015 |
Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Brentuximab Vedotin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Hodgkin Disease; Humans; Immunoconjugates; Male; Middle Aged; Treatment Outcome | 2016 |
Bendamustine combined regimen for Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials, Phase II as Topic; Disease Progression; Disease-Free Survival; Hodgkin Disease; Humans; Remission Induction; Treatment Outcome | 2016 |
Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; France; Humans; Kaplan-Meier Estimate; Logistic Models; Lymphatic Metastasis; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Proportional Hazards Models; Recurrence; Retrospective Studies; Time Factors; Treatment Outcome | 2016 |
Multiple myeloma, version 1.2013.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Humans; Hydroxamic Acids; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Vorinostat | 2013 |
Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Salvage Therapy | 2007 |